Handelsbanken Fonder’s Celldex Therapeutics CLDX Stock Holding History

Handelsbanken Fonder’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Buy	27,200 +1,300	+5%	+$42K	﹤0.01%	1137
2026 Q1	$822K	Hold	25,900	–	–	﹤0.01%	1126
2025 Q4	$703K	Buy	25,900 +4,300	+20%	+$113K	﹤0.01%	1190
2025 Q3	$559K	Hold	21,600	–	–	﹤0.01%	1224
2025 Q2	$440K	Buy	21,600 +500	+2%	+$9.73K	﹤0.01%	1296
2025 Q1	$383K	Hold	21,100	–	–	﹤0.01%	1329
2024 Q4	$533K	Buy	21,100 +7,300	+53%	+$198K	﹤0.01%	1259
2024 Q3	$469K	Buy	13,800 +2,600	+23%	+$99.1K	﹤0.01%	1271
2024 Q2	$415K	Buy	11,200 +3,100	+38%	+$117K	﹤0.01%	1238
2024 Q1	$340K	Hold	8,100	–	–	﹤0.01%	1337
2023 Q4	$321K	Buy	+8,100	New	+$238K	﹤0.01%	1363
2023 Q2	–	Sell	-5,800	Closed	-$209K	–	1584
2023 Q1	$209K	Hold	5,800	–	–	﹤0.01%	1437
2022 Q4	$259K	Sell	5,800 -3,100	-35%	-$111K	﹤0.01%	1324
2022 Q3	$250K	Hold	8,900	–	–	﹤0.01%	1345
2022 Q2	$240K	Hold	8,900	–	–	﹤0.01%	1442
2022 Q1	$303K	Hold	8,900	–	–	﹤0.01%	1512
2021 Q4	$344K	Buy	+8,900	New	+$388K	﹤0.01%	1564

Other funds holding CLDX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Handelsbanken Fonder's CLDX Position: Q2 2026 in Review

Handelsbanken Fonder increased its Celldex Therapeutics (CLDX) stake by 5% in Q2 2026, buying an estimated $42K and bringing the position to 27,200 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

Handelsbanken Fonder first reported a position in CLDX in Q4 2021 and has held it in 17 quarters since. 16 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Handelsbanken Fonder held 27,200 shares of Celldex Therapeutics worth $1.01M as of Q2 2026.
Handelsbanken Fonder bought 1,300 Celldex Therapeutics shares in Q2 2026, an estimated $42K.
Celldex Therapeutics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1137 holding.
Handelsbanken Fonder first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 17 quarters since.
16 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.